Title:
TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) WITH VENETOCLAX FAILURE
Document Type and Number:
WIPO Patent Application WO/2020/191326
Kind Code:
A8
Abstract:
Provided herein are various regimens for treating acute myeloid leukemia (AML) in subjects (e.g, patients) who have undergone one or more prior anti-AML therapies involving venetoclax, and have shown disease progression after the one or more prior therapies. The treatment regimens disclosed herein involve alvocidib, either as a monotherapy, or in combination with cytarabine or a hypomethylating agent, such as decitabine or azacitidine. The treatment regimens disclosed herein do not involve combination therapy of alvocidib with venetoclax.
Inventors:
BEARSS DAVID (US)
ANTHONY STEPHEN (US)
MCCULLAR MICHAEL (US)
SMITH SUSAN (US)
ANTHONY STEPHEN (US)
MCCULLAR MICHAEL (US)
SMITH SUSAN (US)
Application Number:
PCT/US2020/023939
Publication Date:
October 29, 2020
Filing Date:
March 20, 2020
Export Citation:
Assignee:
SUMITOMO DAINIPPON PHARMA ONCOLOGY INC (US)
International Classes:
A61K31/337; A61K31/395; A61K31/4188
Attorney, Agent or Firm:
BALICKY, Eric, M. et al. (US)
Download PDF:
Previous Patent: FLEXIBLE CIRCUIT DESIGN FOR MONITORING PHYSICAL BODIES
Next Patent: SUBWAVELENGTH ANTENNAS, DRIVERS, AND SYSTEMS
Next Patent: SUBWAVELENGTH ANTENNAS, DRIVERS, AND SYSTEMS